Exact Sciences Q1 EPS Estimate Boosted by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS) – Equities research analysts at Leerink Partnrs boosted their Q1 2025 earnings estimates for shares of Exact Sciences in a research note issued on Thursday, February 20th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of ($0.06) for the quarter, up from their prior forecast of ($0.10). The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.26 EPS and Q4 2026 earnings at $0.34 EPS.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.23. The business had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%.

Other equities analysts have also recently issued research reports about the stock. Citigroup lowered their target price on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Sanford C. Bernstein boosted their target price on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group decreased their price objective on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. BTIG Research raised their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, The Goldman Sachs Group cut their price objective on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $72.06.

Exact Sciences Trading Down 0.5 %

Exact Sciences stock opened at $49.26 on Monday. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The company has a market capitalization of $9.15 billion, a price-to-earnings ratio of -8.84 and a beta of 1.24. Exact Sciences has a 12 month low of $40.62 and a 12 month high of $79.62. The business’s fifty day simple moving average is $54.91 and its two-hundred day simple moving average is $60.04.

Hedge Funds Weigh In On Exact Sciences

Several hedge funds and other institutional investors have recently modified their holdings of EXAS. Chicago Partners Investment Group LLC boosted its position in Exact Sciences by 1.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock valued at $651,000 after buying an additional 158 shares during the last quarter. Perigon Wealth Management LLC boosted its position in Exact Sciences by 3.2% during the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock valued at $474,000 after purchasing an additional 264 shares during the period. Sanctuary Advisors LLC increased its holdings in shares of Exact Sciences by 2.0% in the 4th quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock worth $763,000 after acquiring an additional 269 shares during the period. Daiwa Securities Group Inc. increased its position in Exact Sciences by 2.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company’s stock valued at $812,000 after acquiring an additional 300 shares during the period. Finally, Huntington National Bank grew its position in Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after buying an additional 352 shares in the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.